Surgery Partners, Inc. Announces Third Quarter 2026 Results
Surgery Partners reported Q3 2026 revenue of $815.3 million, down 0.8% year-over-year on the Idaho Falls divestiture, with a $21.1 million net loss attributable to shareholders and Adjusted EBITDA of $132.7 million versus $136.4 million a year ago. Underlying momentum was solid: same-facility revenues rose 6.0% on a 5.8% increase in revenue per case, and year-to-date revenue grew 2.1% to $2,475.1 million. The bigger news is an amended merger agreement with HealthSpan Partners that raises consideration to $25.00 per share in cash — an enterprise value of up to ~$6.0 billion — following an unsolicited competing proposal.
Key figures
- Revenue
- 815300000
- Guidance
- Guidance withdrawn; no earnings call due to pending merger
- Deal Value Usd
- 6000000000
- Cash
- 354500000
- Ticking fee rate
- 10% per annum on $25.00 per share after March 1, 2027
- Adjusted ebitda q3
- 132700000
- Net debt to ebitda
- 4.4
- Adjusted ebitda ytd
- 360200000
- Merger price per share
- 25
- Operating cash flow q3
- 103500000
- Same facility cases growth q3
- 0.2%
- Same facility revenue growth q3
- 6.0%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.